만성 바이러스성 B형 간염 환자에서 HBeAg이 혈청전환된 1례 = A Case Report of HBeAg Seroconversion in Chronic Viral Hepatitis B

다국어 초록 (Multilingual Abstract)

Objectives: The purpose of this case study is to report the efficacy and safety of treatment with Korean medicine of a patient with HBeAg-positive chronic viral hepatitis B.Methods: The patient took Korean medicine (mainly Injinchunggan-tang-gamibang) from July 20th, 2010, to March 14th, 2016, without any antiviral or interferon therapy. Changes to laboratory records, abdomen ultrasonography, and clinical symptoms were reviewed.Results: The laboratory records showed that AST, ALT, and HBV DNA had decreased to normal ranges, and HBeAg showed seroconversion. Clinical symptoms also improved after taking Korean medicine.Conclusion: The results suggest that treatment with Korean medicine and without antiviral or interferon therapy could be effective for HBeAg-positive chronic hepatitis B.

참고문헌 (Reference)

1 이중민, "말디토프 질량 분석을 이용한 한국인의 B형간염 바이러스유전자형 및 임상적 의의에 대한 재평가" 대한간학회 10 (10): 260-270, 2004

2 정윤종, "만성 B형 간염을 동반한 초기 간경변 환자에서 茵蔯淸肝湯 투여 관찰한 5례" 대한한방내과학회 27 (27): 1014-1026, 2006

3 천재희, "단일 기관에서 치료한 간세포암종 1,078예의 임상 백서" 대한간학회 10 (10): 288-297, 2004

4 Chan Ho Park, "Treatment of Solitary Extramedullary Plasmacytoma of the Stomach with Endoscopic Submucosal Dissection" 거트앤리버 발행위원회 3 (3): 334-337, 2009

5 Ministry of Helalth & Welfare KCfDCaP, "The Fourth Korea National Health and Nutrition Examination Survey (KNHANES IV), 2010. Health Examination" Ministry of Helalth &Welfare 2012

6 Hong SH, "The Effects of Injinchunggantang-derivative on Cell Viability, Cell Cycle Progression and Apoptosis of Hepatocytes" 19 (19): 337-372, 1998

7 장은경, "The Effects of Injincheonggan-tang on Two Patients with HBeAg-Negative Chronic Hepatitis B : Case Report" 대한한의학회 35 (35): 69-78, 2014

8 Ko H, "The Effects of 5kinds of Injinsaryung-San fractions on Cell Viablity, Cell Cycle Progression and Fas-mediated Apoptosis of HepG2 Cells" 21 (21): 174-185, 2000

9 Park YJ, "The Effect of Injinchunggantang-derivative on Proliferation of Hepatocyte" 19 (19): 145-164, 1998

10 Kang KT, "The Effect of Inchinchunggantang-derivative on Mouse Virus Hepatitis(MHV-2M) and Water Immersion Stress" 20 (20): 133-150, 1997

11 Gupta SK, "Tenofovir-associated Fanconi syndrome:review of the FDA adverse event reporting system" 22 : 99-103, 2008

12 Liaw YF, "Tenofovir disoproxil fumarate (TDF), emtricitabine/TDF, and entecavir in patients with decompensated chronic hepatitis B liver disease" 53 : 62-72, 2011

13 Kim CG, "Study on the Maternal Serum Alpha-Fetoprotein During Pregnancy" 29 (29): 1240-1255, 1986

14 Hong JW, "Study of Korean Medicine Liver System" Publishing & Printing Co. Nado 65-138, 2015

15 Koteiche HA, "Structure of the substrate binding pocket of the multidrug transporter EmrE: site-directed spin labeling of transmembrane segment 1" 42 : 6099-6105, 2003

16 Song IS, "Seasonal and annual variations on occurrence of HBsAg and acquisition of anti-HBs in Korea" 22 : 1007-1015, 1979

17 Osborn M, "Safety and efficacy of entecavir for the treatment of chronic hepatitis B" 4 : 55-64, 2011

18 Chen CJ, "Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level" 295 : 65-73, 2006

19 Iloeje UH, "Risk Evaluation of Viral Load Elevation and Associated Liver Disease/Cancer-In HBV (the REVEAL-HBV) Study Group. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load" 130 : 678-686, 2006

20 Sim JG, "Prevalence and its changes of hepatitis B viral markers from 1988to 1993 in Korean children" 38 : 1535-1539, 1995

21 Kim SR, "Organizing Committee of Japan-Korea Liver Symposium. Epidemiology of hepatocellular carcinoma in Japan and Korea" 75 (75): 13-16, 2008

22 Lee BS, "Nationwide seroepidemiology of hepatitis B virus infection in South Korea in 2009 emphasizes the coexistence of HBsAg and anti-HBs" 85 : 2013

23 Kim H, "Molecular epidemiology of hepatitis B virus (HBV) genotypes and serotypes in patients with chronic HBV infection in Korea" 50 : 52-57, 2007

24 Manns MP, "Long-term safety and tolerability of entecavir in patients with chronic hepatitis B in the rollover study ETV-901" 11 : 361-368, 2012

25 Manns MP, "Long-term safety and tolerability of entecavir in patients with chronic hepatitis B in the rollover study ETV-901" 11 : 361-368, 2012

26 Hsu YS, "Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B" 35 : 1522-1527, 2002

27 Tenney DJ, "Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naive patients is rare through 5 years of therapy" 49 : 1503-1514, 2009

28 Si Hyun Bae, "Hepatitis B Virus Genotype C Prevails Among Chronic Carriers of the Virus in Korea" 대한의학회 20 (20): 816-820, 2005

29 Gish RG, "Entecavir therapy for up to 96 weeks in patients with HBeAgpositive chronic hepatitis B" 133 : 1437-1444, 2007

30 Shim JH, "Efficacy of entecavir in treatment-naive patients with hepatitis B virusrelated decompensated cirrhosis" 52 : 176-182, 2010

31 Lee JH, "Effects of Five Fractions of Artemisia capillaris THUNB on TGFβ1-induced Apotosis in HepG2 Cells" 20 (20): 53-61, 2000

32 Shin SM, "Effect of Injin Fraction on Hepatic Fibrosis induced by TGF-β1" 22 (22): 141-155, 2001

33 Chae HB, "Current status of liver diseases in Korea: hepatitis B" 15 (15): S13-S24, 2009

34 Livingston SE, "Clearance of hepatitis B e antigen in patients with chronic hepatitis B and genotypes A, B, C, D, and F" 133 : 1452-1457, 2007

35 The Korean Association for the Study of the Liver, "2015 Chronic Hepatitis B Clinical Practive Guideline" Publishing & Printing Co. Jin 32-72, 2015

36 Korea Centers for Disease Control and Prevention, "2006 Disease Control White Paper" Korea Centers for Disease Control and Prevention 144-, 2007